446 related articles for article (PubMed ID: 26938635)
1. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
Thayer S; Chow W; Korrer S; Aguilar R
Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
[TBL] [Abstract][Full Text] [Related]
2. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
3. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Wysham CH; Lefebvre P; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Chow W; Pfeifer M; Duh MS
BMC Endocr Disord; 2017 Jun; 17(1):32. PubMed ID: 28595617
[TBL] [Abstract][Full Text] [Related]
4. HbA
Thayer S; Aguilar R; Korrer S; Chow W
Clin Ther; 2017 Oct; 39(10):2061-2072. PubMed ID: 28943114
[TBL] [Abstract][Full Text] [Related]
5. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
6. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
Wysham CH; Lefebvre P; Pilon D; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Duh MS; Ingham M
J Diabetes Complications; 2019 Feb; 33(2):140-147. PubMed ID: 30554838
[TBL] [Abstract][Full Text] [Related]
7. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
Cai J; Divino V; Burudpakdee C
Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting.
Buysman EK; Chow W; Henk HJ; Rupnow MF
Curr Med Res Opin; 2015 Jan; 31(1):137-43. PubMed ID: 25356602
[TBL] [Abstract][Full Text] [Related]
9. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
10. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
Lefebvre P; Pilon D; Robitaille MN; Lafeuille MH; Chow W; Pfeifer M; Duh MS
Curr Med Res Opin; 2016 Jun; 32(6):1151-9. PubMed ID: 27115475
[TBL] [Abstract][Full Text] [Related]
11. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care setting.
Chow W; Buysman E; Rupnow MF; Aguilar R; Henk HJ
Curr Med Res Opin; 2016; 32(1):13-22. PubMed ID: 26414434
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin.
Buysman EK; Anderson A; Bacchus S; Ingham M
Adv Ther; 2017 Apr; 34(4):937-953. PubMed ID: 28251556
[TBL] [Abstract][Full Text] [Related]
14. Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice.
Bailey RA; Schwab P; Xu Y; Pasquale M; Renda A
Clin Ther; 2016 Sep; 38(9):2046-2057.e2. PubMed ID: 27567160
[TBL] [Abstract][Full Text] [Related]
15. An observational study of glycemic control in canagliflozin treated patients.
Meckley LM; Miyasato G; Kokkotos F; Bumbaugh J; Bailey RA
Curr Med Res Opin; 2015 Aug; 31(8):1479-86. PubMed ID: 25986535
[TBL] [Abstract][Full Text] [Related]
16. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.
Lafeuille MH; Grittner AM; Gravel J; Bailey RA; Martin S; Garber L; Duh MS; Lefebvre P
J Med Econ; 2015 Feb; 18(2):113-25. PubMed ID: 25350645
[TBL] [Abstract][Full Text] [Related]
17. Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida.
Tanton D; Duh MS; Lafeuille MH; Lefebvre P; Pilon D; Zhdanava M; Emond B; Inman D; Bailey RA
Curr Med Res Opin; 2018 Jun; 34(6):1099-1115. PubMed ID: 29468896
[TBL] [Abstract][Full Text] [Related]
18. Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
Fushimi Y; Obata A; Sanada J; Iwamoto Y; Mashiko A; Horiya M; Mizoguchi-Tomita A; Nishioka M; Kan Y; Kinoshita T; Okauchi S; Hirukawa H; Kohara K; Tatsumi F; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Res; 2020; 2020():4861681. PubMed ID: 32337293
[TBL] [Abstract][Full Text] [Related]
19. Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
Mody R; Yu M; Grabner M; Boye K; Teng CC; Kwan AYM
Clin Ther; 2020 Nov; 42(11):2184-2195. PubMed ID: 33256915
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
Garcia de Lucas MD; Pérez Belmonte LM; Suárez Tembra M; Olalla Sierra J; Gómez Huelgas R
Diabetes Metab; 2018 Sep; 44(4):373-375. PubMed ID: 29859992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]